# How Intense Is Effective? Exploring Aerobic Exercise Intensity for Knee Osteoarthritis Through a Bayesian NetworkMeta-Analysis

**Authors:** Luis Cabrera-Durán, Javier Palomares-Fernández, Ignacio Canitrot-González, Paride Crisafulli, Carlos Donato Cabrera-López, José Fierro-Marrero

PMC · DOI: 10.3390/healthcare14040451 · Healthcare · 2026-02-11

## TL;DR

This study examines the effectiveness of different aerobic exercise intensities for knee osteoarthritis but finds insufficient evidence to determine the best intensity.

## Contribution

The novel contribution is a Bayesian network meta-analysis exploring aerobic exercise intensity effectiveness for knee osteoarthritis.

## Key findings

- Comparisons between aerobic exercise intensities showed non-significant, imprecise results.
- Evidence certainty was rated as very low due to high risk of bias and indirect comparisons.
- Clinicians are advised to use a patient-centered approach and combine aerobic exercise with other interventions.

## Abstract

Introduction: Knee osteoarthritis (KOA) is characterized by pain, stiffness, and functional limitation. Aerobic exercise (AE) is a key treatment with proven benefits. Aims: To determine the most effective AE intensity for KOA. Methods: Searches were performed in seven databases, including randomized controlled trials with AE-only groups. Outcomes assessed were pain, walking and sit-to-stand performance, stiffness, and disability. Methodological quality and bias were evaluated. Bayesian random-effects network meta-analyses compared AE intensities, reporting standardized mean differences (Hedges’ g) with 95% credible intervals. Certainty of evidence was rated using GRADE. Results: Fifteen studies were included (mean PEDro score: 5.93), showing “some concerns” or “high risk” of bias. Two meta-analyses (pain and walking performance) were conducted. Comparisons between AE intensities showed non-significant, imprecise results with very low certainty of evidence. Conclusions: Evidence is insufficient to identify the optimal AE intensity for KOA. Limitations include high risk of bias, wide credible intervals, and reliance on indirect comparisons. In this context, clinicians should apply a structured, patient-centered approach to AE prescription, considering gradual progression and monitoring of tolerance, and combine AE with other recommended interventions. High-quality trials with direct comparisons of AE intensity should be conducted for this inconclusive gap.

## Full-text entities

- **Genes:** MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** metabolic syndrome (MESH:D024821), inflammation (MESH:D007249), injury to (MESH:D014947), Pain (MESH:D010146), sleep disturbance (MESH:D012893), diabetes (MESH:D003920), anxiety (MESH:D001007), swelling (MESH:D004487), obesity (MESH:D009765), knee pain (MESH:D046788), overweight (MESH:D050177), abnormal joint tissue metabolism (MESH:D008659), OA (MESH:D010003), cartilage degradation (MESH:D002357), knee stiffness (MESH:D007718), hip OA (MESH:D015207), osteophyte (MESH:D054850), stiffness (MESH:C566112), hypertension (MESH:D006973), loss of normal joint function (MESH:D006315), insulin resistance (MESH:D007333), joint swelling (MESH:D007592), KOA (MESH:D020370), musculoskeletal pathologies (MESH:D009140), joint degeneration (MESH:D009410), AE (MESH:D000092202), disability (MESH:D009069)
- **Chemicals:** oxygen (MESH:D010100), neurotrophic (-), serotonin (MESH:D012701)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940493/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940493/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940493/full.md

---
Source: https://tomesphere.com/paper/PMC12940493